High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects
出版年份 2022 全文链接
标题
High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects
作者
关键词
-
出版物
REVUE NEUROLOGIQUE
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-09-29
DOI
10.1016/j.neurol.2022.06.012
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
- (2022) Eric Karran et al. NATURE REVIEWS DRUG DISCOVERY
- Amyloid-Related Imaging Abnormalities and β-Amyloid–Targeting Antibodies
- (2022) Massimo Filippi et al. JAMA Neurology
- Alzheimer disease neuropathology in a patient previously treated with aducanumab
- (2022) Edward D. Plowey et al. ACTA NEUROPATHOLOGICA
- A Bayesian perspective on Biogen's aducanumab trial
- (2022) Anna G. M. Temp et al. Alzheimers & Dementia
- Aduhelm, the newly approved medication for Alzheimer’s disease: what epidemiologists can learn and what epidemiology can offer
- (2022) M Maria Glymour et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US
- (2022) Eric L. Ross et al. JAMA Neurology
- Donanemab in Early Alzheimer’s Disease
- (2021) Mark A. Mintun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease
- (2021) Edo Richard et al. Alzheimers & Dementia
- A Middle Ground for Accelerated Drug Approval—Lessons From Aducanumab
- (2021) Ezekiel J. Emanuel JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Geriatrician, the Primary Care Physician, Aducanumab and the FDA Decision: From Frustration to New Hope
- (2021) Bruno J. Vellas Journal of Nutrition Health & Aging
- Instead of wasting money on aducanumab, pay for programs proven to help people living with dementia
- (2021) Lauren J. Hunt et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
- (2021) Bruno Dubois et al. LANCET NEUROLOGY
- A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
- (2021) Stephen Salloway et al. NATURE MEDICINE
- Can we learn lessons from the FDA’s approval of aducanumab?
- (2021) Kathy Y. Liu et al. Nature Reviews Neurology
- Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity
- (2021) Roos J. Jutten et al. NEUROLOGY
- Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease
- (2021) Stephen Salloway et al. NEUROLOGY
- Revisiting FDA Approval of Aducanumab
- (2021) G. Caleb Alexander et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Appropriate Use of Accelerated Approval — Aducanumab for Alzheimer’s Disease
- (2021) Billy Dunn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aducanumab for Alzheimer’s disease: A regulatory perspective
- (2021) Robert Nisticò et al. PHARMACOLOGICAL RESEARCH
- Treatments for Alzheimer's disease emerge
- (2021) Dennis J. Selkoe SCIENCE
- Approval of Aducanumab for Alzheimer Disease—the FDA’s Perspective
- (2021) Billy Dunn et al. JAMA Internal Medicine
- Fulfilling the Mandate of the US Food and Drug Administration’s Accelerated Approval Pathway
- (2021) Bishal Gyawali et al. JAMA Internal Medicine
- US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
- (2021) Vincent Planche et al. JAMA Neurology
- Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease
- (2021) William L. Herring et al. Neurology and Therapy
- TRAILBLAZER‐ALZ Study: Dynamics of amyloid reduction after donanemab treatment
- (2021) Sergey Shcherbinin et al. Alzheimers & Dementia
- What the Aducanumab Approval Reveals About Alzheimer Disease Research
- (2021) Jennifer J. Manly et al. JAMA Neurology
- Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
- (2019) Steven M. Greenberg et al. Nature Reviews Neurology
- Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
- (2019) Gregory Klein et al. Alzheimers Research & Therapy
- NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
- (2018) Clifford R. Jack et al. Alzheimers & Dementia
- Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
- (2018) Christopher H. van Dyck BIOLOGICAL PSYCHIATRY
- Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
- (2018) Michal Sarfaty et al. EUROPEAN UROLOGY
- Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
- (2018) Lawrence S. Honig et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies
- (2018) H. Robert Brashear et al. JOURNAL OF ALZHEIMERS DISEASE
- Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward
- (2017) Oriana Ciani et al. VALUE IN HEALTH
- A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
- (2017) Susanne Ostrowitzki et al. Alzheimers Research & Therapy
- The amyloid hypothesis of Alzheimer's disease at 25 years
- (2016) Dennis J Selkoe et al. EMBO Molecular Medicine
- The amyloid cascade hypothesis: are we poised for success or failure?
- (2016) Eric Karran et al. JOURNAL OF NEUROCHEMISTRY
- ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
- (2016) Jinping Wang et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs
- (2016) Chul Kim et al. MAYO CLINIC PROCEEDINGS
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET
- (2015) William E. Klunk et al. Alzheimers & Dementia
- Amyloid-β11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
- (2015) Enchi Liu et al. NEUROLOGY
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarkers and surrogate endpoints in clinical trials
- (2012) Thomas R. Fleming et al. STATISTICS IN MEDICINE
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Guy M. McKhann et al. Alzheimers & Dementia
- The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Marilyn S. Albert et al. Alzheimers & Dementia
- What is the clinically relevant change on the ADAS-Cog?
- (2011) Anette Schrag et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
- (2009) S. Salloway et al. NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now